Dimerix Limited · ASX:DXB

Dimerix — Shareholder Meeting (November 2014)

33 slides from Dimerix's shareholder meeting presentation, November 2014

  1. Slide 1: Clinical phase biotech company with development pipeline

    Slide 1: Clinical phase biotech company with development pipeline

    Clinical phase biotech company with development pipeline AGM - November 2014

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer This presentation prepared by Dimerix Bioscience Pty Ltd, in the process of converting to Dimerix Biosciences Limited, ("Company" or “Dimerix”) does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitati

  3. Slide 3: Dimerix Overview

    Slide 3: Dimerix Overview

    Dimerix Overview Lead program: DMX200 – PII asset for treatment of Chronic Kidney Disease − Human PoC study commenced AusBn Hospital (Funded) − Development program focused on fast-­‐track to IND and orphan designaBon − CombinaBon of 2 drugs with extensive human data − Patent applicaBons in NaBonal p

  4. Slide 4: Dimerix Programs

    Slide 4: Dimerix Programs

    Dimerix Programs Ethics and site iniBaBon complete at AusBn Hospital Phase II ready clinical program, mul5ple pipeline opportuni5es, plus top 10 pharma engagement for development platform

  5. Slide 5: Team

    Slide 5: Team

    Dimerix

  6. Slide 6: Executive Board & Management

    Slide 6: Executive Board & Management

    Executive Board & Management Exec. Chairman: • Co-founder of Dimerix and iCeutica (acquired in 2011 and now Dr James Williams with 2 FDA drug approvals) BSc(Hons), PhD, MBA • Co-founder of Yuuwa Capital ($40M venture capital fund) • Former Managing Director of Resonance Health and Argus Biomedical (

  7. Slide 7: Non-Executive Directors

    Slide 7: Non-Executive Directors

    Non-Executive Directors Director: • Current – Medical Director INC Research Dr David Fuller • 20+ years international experience commercialising BPharm, MBBS therapeutic products • Former Executive Director Genzyme UK and Chief Medical Officer of Arana Therapeutics (valued at >$300 million when take

  8. Slide 8: Key Advisors

    Slide 8: Key Advisors

    Key Advisors Chief Scientific Adviser • Inventor Dimerix technology A/Prof Kevin Pfleger • Head Molecular Endocrinology and Pharmacology at the MA (Camb.) PhD Harry Perkins Institute of Medical Research (Edin.) • Australian Research Council Future Fellow • Recipient of Young Scientist of the Year Aw

  9. Slide 9: GPCR-Heteromer Identification Technology

    Slide 9: GPCR-Heteromer Identification Technology

    GPCR-Heteromer Identification Technology A powerful discovery platform

  10. Slide 10: GPCR – From a signalling pathway to a profile

    Slide 10: GPCR – From a signalling pathway to a profile

    GPCR – From a signalling pathway to a profile GPCR monomer/homomer signaling GPCR heteromer signaling and / or and / Different G-protein G-protein or β-arrestin Different mediated mediated mediated G-protein- β-arrestin pathways pathways pathways mediated mediated pathways pathways Knowledge and opt

  11. Slide 11: GPCR-HIT: CCR2/Rluc8 and AT1R recruitment of β-arrestin2

    Slide 11: GPCR-HIT: CCR2/Rluc8 and AT1R recruitment of β-arrestin2

    GPCR-HIT:CCR2/Rluc8 and AT1R recruitment of β-arrestin2 CCR2-­‐Rluc8 AT1R Angiotensin II β-arrestin Rluc8 Rluc8 Venus β-arrestin BRET Venus A signal is only generated when the receptors are in functional proximity

  12. Slide 12: Identification of CCR2 and heteromer

    Slide 12: Identification of CCR2 and heteromer

    Identification of CCR2 and heteromer More than additive effect of co-treating with agonists for both receptors

  13. Slide 13: CCR2/AT1R heteromer: In vitro antagonist studies

    Slide 13: CCR2/AT1R heteromer: In vitro antagonist studies

    CCR2/AT1R heteromer: In vitro antagonist studies Require treatment with both CCR2 antagonist (RS504393) and AT1R antagonist (Irbesartan) to reduce signal from dual CCL2 and AngII stimulation. Dimerix sought to test this in vivo

  14. Slide 14: DMX200 Clinical Program & Market Need CKD

    Slide 14: DMX200 Clinical Program & Market Need CKD

    DMX200 Clinical Program & Market Need CKD

  15. Slide 15: DMX200: Phase II Clinical Trial

    Slide 15: DMX200: Phase II Clinical Trial

    DMX200: Phase II Clinical Trial • Treatment of Proteinuria in CKD paBents • Study design: Fixed dose combinaBon of Irbesartan + Propagermanium • Enrollment: Up to 60 paBents in two Parts • Part A: Dose escalation – Up to 5 doses x 1 month, then 3 months at maximal dose • Part B: “Best dose” combinaB

  16. Slide 16: Chronic Kidney Disease (CKD) US patients

    Slide 16: Chronic Kidney Disease (CKD) US patients

    Chronic Kidney Disease (CKD) 26 million US patients: 8.5m patients at or beyond Stage 3 Stage Kidney Function Prevalence 1 Normal kidney function but altered urine findings, structural abnormalities or genetic traits 2 Mildly reduced kidney function, and other findings point to kidney disease 3 Mode

  17. Slide 17: Causes of CKD: segmented market

    Slide 17: Causes of CKD: segmented market

    Causes of CKD: segmented market = different regulatory and reimbursement pathways Disease Example Prevalence Diabetic Kidney Diabetes Type 1, Diabetes Type 2 34% Disease Non-diabetic Glomerular Diseases 24% Kidney - Primary (unknown), AutoImmune, Infection, Drugs Disease Vascular Diseases 14% - Hype

  18. Slide 18: Chronic Kidney Disease: Nephrotic Syndrome

    Slide 18: Chronic Kidney Disease: Nephrotic Syndrome

    Chronic Kidney Disease: Nephrotic Syndrome • Non-specific disorder where kidneys are damaged; characterised by proteinuria; may also have hypoalbuminemia, hyperlipidemia and edema. • Gold standard diagnosis of nephrotic syndrome is 24 hour urine protein measurement (proteinuria) • Regulatory pathway

  19. Slide 19: Limited Competition for Nephrotic Syndrome

    Slide 19: Limited Competition for Nephrotic Syndrome

    Limited Competition for Nephrotic Syndrome: Questcor – mechanism of action not fully understood Steroids ACTHAr InjecBble Gel Company MulBple Questcor Naturally occurring adrenocorBcotrophic Mechanism Steroid hormone (ACTH) analogue Side effects Multiple –steroid effects on growth, adrenal gland, ot

  20. Slide 20: Competition / Comparators

    Slide 20: Competition / Comparators

    Competition / Comparators Dimerix

  21. Slide 21: Questcor: Acquired for $5.6 billion

    Slide 21: Questcor: Acquired for $5.6 billion

    Questcor: Acquired for $5.6 billion (August 2014) • Acthar gel (injection only). • Acthar is a generic adrenocorticotrophic hormone (ACTH) analogue, or steroid, shown to have advantages where paBents are otherwise steroid resistant or cannot tolerate steroids. Long term steroid treatments are not fa

  22. Slide 22: Chemocentryx: Mkt Cap US$203m

    Slide 22: Chemocentryx: Mkt Cap US$203m

    Chemocentryx: Mkt Cap US$203m (NASDAQ Nov 2014) • BiopharmaceuBcal company targeting chemokine receptor targets. • Lead program CCX140 targeting chemokine CCR2 receptor in two Phase II clinical trials for diabetic nephropathy. • Second generation compound in Phase 1 clinical trial for other renal di

  23. Slide 23: Fibrotech: Private Australian company

    Slide 23: Fibrotech: Private Australian company

    Fibrotech: Private Australian company • VC backed company recently announced to be acquired by Shire PharmaceuBcals • US$75 million upfront consideraBon, plus undisclosed milestones • Fibrotech program in Phase 1b for diabeBc nephropathy • Shire has announced it will target orphan FSGS in first insta

  24. Slide 24: Comparable NASDAQ GPCR Platform Companies

    Slide 24: Comparable NASDAQ GPCR Platform Companies

    Comparable NASDAQ GPCR Platform Companies Trevena Inc Receptos Inc IPO 5 Feb 2014 14 Jan 2014 Market Cap (Raise) ~$144M ($65m) $3.26B ($117m) (November 2014) Clinical Assets 1xPhase II; 1xPhase III; 1xPhase I 1xPhase II; 1xPhase I PlaNorm Knowhow around GPCR Structure based discovery Biased Ligands

  25. Slide 25: Capital Structure & Finance

    Slide 25: Capital Structure & Finance

    Capital Structure & Finance Dimerix

  26. Slide 26: Cap Table

    Slide 26: Cap Table

    Cap Table Shareholders Ordinary % Holding Peter Meurs 23,939,126 32.8 Pre-­‐IPO 9,375,000 12.9 Top up to seed* 5,625,000 7.7 SRV Custodians Pty Ltd 7,390,496 10.1 Yodambao Pty Ltd 7,056,276 9.7 Nullaki Services Pty Ltd aN Anvil Bay Trust 3,495,203 4.8 Toroha Pty Ltd aN White Family Trust 2,949,100 4

  27. Slide 27: Development timeline and Financing

    Slide 27: Development timeline and Financing

    Development timeline and Financing

  28. Slide 28: Further Information

    Slide 28: Further Information

    Further Information James Williams, Chairman Corporate Office: +61 409 050 519 L2/25 Flinders Lane, Melbourne, VIC 3000 james@dimerix.com Australia Ph: +61 409 050 519 Dimerix Bioscience Ltd Fax: +61 8 9355 5694 ACN 112 223 417 www.dimerix.com

  29. Slide 29: Regulatory Approach

    Slide 29: Regulatory Approach

    Regulatory Approach Dimerix

  30. Slide 30: Regulatory path for orphan indication

    Slide 30: Regulatory path for orphan indication

    Regulatory path for orphan indication - small numbers and approx. 6 months duration Treatment of Proteinuria in Membranous Nephropathy Patients Nephrotic Syndrome Study design: Regulatory -­‐ 0.5mL injections 5/week vs placebo injection 5/week Approval Path -­‐ 1.0mL injections 2/week vs placebo inj

  31. Slide 31: Core Intellectual Property

    Slide 31: Core Intellectual Property

    Core Intellectual Property Combination Therapy: PCT Number: AU2012/000014 International Filing Date: 11 January 2012 Status: National Phase entered Applicant: Dimerix Bioscience Pty Ltd Inventors: PFLEGER, Kevin Donald George; MCCALL, Elizabeth; WILLIAMS, James Applications: Combinations of drugs fo

  32. Slide 32: Example: revenue impact of orphan designations

    Slide 32: Example: revenue impact of orphan designations

    Example: revenue impact of “orphan designations” Source: Business Insights source Business Insights Niche Blockbuster Orphan Ultra orphan Target Drug Lipitor Erbitux Diacomit Replagal Hyperchole-­‐ Colorectal Fabry’s IndicaBon SMEI sterolemia cancer disease Number of 1 million + 100,000 10,000 5,000

  33. Slide 33: Retrophin: Mkt Cap US$372m

    Slide 33: Retrophin: Mkt Cap US$372m

    Retrophin: Mkt Cap US$372m (1 June 2014) • Clinical program for sub-­‐set of chronic kidney disease (focal segmental glomerulosclerosis – an orphan indicaBon) plus some pre-­‐clinical compounds. • Lead program RE-­‐021 has a dual antagonist for GPCR receptors -­‐ angiotensin receptor (AT1T2) blocker

Source: Internet Archive copy of dimerix.com

More decks from Dimerix Limited

All 86 Dimerix decks